Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer

Purpose.This retrospective study determined the delayed-type hypersensitivity (DTH) skin test and safety of dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell immunotherapy and the survival compared to chemotherapy in 239 colorectal cancer (CRC) patients.Methods.DTH and safety of the immunotherapy were recorded. The overall survival (OS) and disease free survival curves were compared according to the immunotherapy and/or chemotherapy received with Kaplan-Meier estimates.Results.Of the 70 patients who received immunotherapy, 62.86% had a positive DTH skin test, 38.57% developed fever, 47.14% developed insomnia, 38.57% developed anorexia, 4.29% developed joint soreness, and 11.43% developed skin rash. For 204 resectable CRC patients, median survival time (MST) (198.00 days) was significantly longer in patients with immunotherapy plus chemotherapy than with chemotherapy alone (106.00 days)(P=0.02). For 35 patients with unresectable or postsurgery relapsed CRC and who were confirmed to be dead, no statistical difference was observed in the MST between the patients treated with immunotherapy and with chemotherapy(P=0.41). MST in the patients treated with chemotherapy plus immunotherapy was 154 days longer than that of patients treated with chemotherapy alone(P=0.41).Conclusions.DC vaccination and CIK immunotherapy did not cause severe adverse effects, induce immune response against CRC, and prolong OS.

Download Full-text

Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy

BioMed Research International ◽

10.1155/2014/603871 ◽

2014 ◽

Vol 2014 ◽

pp. 1-5 ◽

Cited By ~ 13

Author(s):

Hui Zhu ◽

Xuejing Yang ◽

Jiali Li ◽

Yanjie Ren ◽

Tianyu Zhang ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Immune Response ◽

Dendritic Cell ◽

Advanced Colorectal Cancer ◽

Killer Cell ◽

Delayed Type Hypersensitivity ◽

Dc Vaccine ◽

Group I

Purpose.To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients.Methods.We recruited 100 patients with unresectable CRC orrelapsed CRC after surgery who received DC vaccine and CIK cells (group immunotherapy, group I), and, as a control, 251 patients who had similar characteristics and underwent similar treatments, except for this immunotherapy (group nonimmunotherapy, group NI). After a follow-up period of 489.2 ± 160.4 days, overall survival (OS) of the two groups was compared using the Kaplan-Meier method.Results.In group I, 62% of patients developed a positive delayed type hypersensitivity response, and most patients showed an improvement in physical strength (75.2%), appetite (74.2%), sleeping (72.1%), and body weight (70.1%). Adverse events were fever (29.5%), insomnia (19.2%), anorexia (9.1%), sore joints (5.4%), and skin rash (1.0%). No toxicity was observed in patients treated with DC vaccine and CIK therapy. OS was significantly longer in group I than in group NI (P= 0.043).Conclusion.DC vaccine and CIK therapy were safe and could induce an immune response against CRC, thereby improving QOL and prolonging OS.

Download Full-text

Faculty Opinions recommendation of Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727595480.793531790 ◽

2017 ◽

Author(s):

John Nemunaitis ◽

Luisa Manning

Keyword(s):

Pancreatic Cancer ◽

Dendritic Cell ◽

Clinical Outcome ◽

Cell Therapy ◽

Killer Cell ◽

Dendritic Cell Vaccine ◽

Cell Vaccine

Download Full-text

Portulaca oleracea L. polysaccharides enhance the immune efficacy of dendritic cell vaccine for breast cancer

Food & Function ◽

10.1039/d0fo02522d ◽

2021 ◽

Author(s):

Guiyan Jia ◽

Xingyue Shao ◽

Rui Zhao ◽

Tao Zhang ◽

Xiechen Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Dendritic Cell ◽

Signaling Pathway ◽

Mechanism Of Action ◽

Dendritic Cell Vaccine ◽

Portulaca Oleracea ◽

Cell Vaccine ◽

Dc Vaccine ◽

Immune Efficacy ◽

Dc Maturation

POL-P3b, as a promising dietary adjuvant for the DC vaccine of breast cancer, could induce DC maturation and the mechanism of action involved in the TLR4/MyD88/NF-κB signaling pathway.

Download Full-text